AbbVie stock holds near $256 after Q2 beat
Published on 08/29/2026 at 11:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (US00287Y1091) stock traded at $256.08 on August 29, 2026 after the company posted second-quarter 2026 revenue of $16.99 billion and adjusted EPS of $3.65, both above consensus. The shares also carried a market value of $452.44 billion, keeping the name among the largest U.S. health care stocks.
Q2 growth still sets the tone
AbbVie said the quarter ended June 30, 2026 produced revenue growth of 10.2 percent from the same period a year earlier, when sales were $15.42 billion. Adjusted EPS rose from $2.97 in the prior-year quarter, a gain of 22.9 percent, while the latest quarter beat the $3.61 estimate by $0.04.
The profit picture was mixed in the details but still solid enough to support the current valuation. The company reported a 9.80 percent net margin, and current-year analyst estimates point to EPS of $14.06 for 2026, only a touch above the company's updated guidance band.
Guidance and consensus
Management set third-quarter 2026 adjusted EPS guidance at $3.84 to $3.88 and trimmed full-year 2026 adjusted EPS guidance to $13.87 to $14.07. Market data also show a consensus target of $275.95 and a 12-month high of $267.47, which places the current quote below the highest recent trading range.
For investors, the important comparison is simple: revenue rose 10.2 percent year over year, EPS increased 22.9 percent, and the stock still trades below the current consensus target. That leaves AbbVie in a position where execution, not story, is doing most of the work.
Skyrizi remains central
Skyrizi remains the most visible representative of AbbVie's post-Humira growth engine, especially in immunology. The latest quarter's double-digit sales growth suggests that newer therapies are still offsetting pressure from older products.
Stock level
AbbVie stock opened at $256.08 on August 29, 2026, with a market cap of $452.44 billion and a 12-month range of $190.75 to $267.47. The current quote sits in the upper half of that range and close to the recent high.
Company profile and market data
Company: AbbVie Inc.
ISIN: US00287Y1091
Ticker: ABBV
Exchange: NYSE
Price (as of August 29, 2026): $256.08 USD
Market cap: $452.44 billion (as of August 29, 2026)
Sector / Industry: Health Care / Pharmaceuticals and Biotechnology
Index membership: S&P 500
More on AbbVie stock
Investor Relations
